USPTO serial 98471236
Serial No. 98471236
Reviewed by CopyMark Law Group
Status 748
- Filing date
- Status date
- Registration date
- —
- Examiner
- NADEAU, MADELINE JEAN
- Law office
- TMEG LAW OFFICE 104
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with Serial No. 98471236?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Abbott Park, IL, US
Abbott Park, IL, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jennifer M. Mikulina
Jennifer M. Mikulina McDermott Will & Schulte LLP444 West Lake Street, Suite 4000Chicago, IL 60606-0029United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 010 | Medical diagnostic instruments for diabetes diagnosis and monitoring; medical diagnostic instruments for analyzing, measuring and testing blood, bodily fluids and tissue; medical diagnostic instruments for in vitro diagnostic testing and analysis, namely, sample handlers, sample preparation equipment, equipment for testing bodily fluids for medical diagnosis; medical diagnostic instruments for microbial screening and identification, analysis of nucleic acid sequences, nucleic acids, genetic materials, infectious agents and pathogens; medical and surgical apparatus and instruments, namely, stents, catheters, guide wires, bioabsorbable stents, drug-eluting stents, scaffolding for catheters and stents for use in vascular procedures; medical apparatus and equipment, namely, patient monitor that is for use in electronic acquisition, capture and transmission of medical device status and patient medical and physiological data used in connection with implantable cardiac devices, and external or implantable cardiac therapeutic or diagnostic devices; medical diagnostic instruments for testing patients for respiratory, community acquired, hospital acquired, sexual health, gastro-enteric, vector borne, blood borne pathogen, and tropical disease infections; medical diagnostic apparatus and incorporated recorded computer software for analyzing medical data and informing treatment decisions, all sold as a unit, for medical diagnostic use; medical apparatus and instruments, namely, blood glucose meters, blood ketone meters, biosensors and biosensor applicators for measuring blood glucose, blood ketone, and blood lactate levels, electrochemical sensors for measuring analyte concentrations in interstitial fluid, electrochemical sensors for monitoring analyte levels in interstitial fluid, electrochemical sensors for monitoring analyte concentrations in bodily fluids, electrochemical sensors for monitoring analyte levels in bodily fluids, electrochemical sensors for monitoring analytes in bodily fluids, needles for injecting insulin, medical infusion pumps for delivering measured amounts of solutions into the bloodstream over time, and insulin pumps; blood, bodily fluid, tissue, and fecal matter medical testing instruments; medical apparatus for monitoring, tracking, and determining analyte concentrations; sensors for monitoring, tracking, and determining analyte concentrations for health purposes; medical apparatus and instruments for monitoring glucose; medical apparatus and instruments for monitoring ketones; instruments and apparatus for monitoring glucose for health purposes; instruments and apparatus for monitoring ketones for health purposes; patient monitoring sensors for monitoring glucose concentrations; patient monitoring sensors for monitoring ketone concentrations; sensor-based glucose monitors for medical purposes; sensor-based ketone monitors for medical purposes; medical devices, namely, catheters and catheter interface modules; medical and surgical catheters; enteral nutritional delivery system, namely, feeding tubes; breastmilk storage bottle; infant formula storage bottle, sold empty; baby bottles; baby nursers | ACTIVE | Oct 5, 2026 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 20, 2026 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Oct 12, 2026 | IUAF | USE AMENDMENT FILED | — |
| Oct 12, 2026 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Apr 1, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 31, 2026 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Mar 31, 2026 | EXT2 | SOU EXTENSION 2 FILED | — |
| Mar 31, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 19, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 18, 2025 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Aug 18, 2025 | EXT1 | SOU EXTENSION 1 FILED | — |
| Aug 18, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 15, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 15, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 15, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 15, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Feb 18, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 18, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 12, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 9, 2025 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Jan 8, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 8, 2025 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 8, 2025 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 8, 2025 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 8, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 8, 2025 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 8, 2025 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 8, 2025 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 8, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 23, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 23, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 30, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 30, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 24, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 24, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 24, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 17, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 16, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 8, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 11, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 27, 2024 | NWAP | NEW APPLICATION ENTERED | — |